What We’re Developing
Science-backed therapies for pets who need more
Gallant is developing ready-to-use mesenchymal stromal cell (MSC) therapies for conditions where current options fall short that target the root cause of disease to support the body’s natural healing response. These therapies are part of a new category of care.
Our Pipeline
Advancing MSC therapies for pets in need
Every therapy in our pipeline advances through FDA’s structured approval process to meet the rigorous standards for safety, effectiveness, and manufacturing quality and consistency.
| Pre-clinical |
proof of concept |
Controlled field study | Pivotal study | Commercially available | |
|---|---|---|---|---|---|
|
Feline Chronic Gingivostomatitis
|
|
||||
|
Feline Osteoarthritis
|
|
||||
|
Canine Osteoarthritis
|
|
||||
|
Feline Chronic Kidney Disease
|
|
||||
|
Canine Atopic Dermatitis
|
|
||||
Therapies in Development
Gallant is advancing a new class of veterinary therapeutics—ready-to-use MSC therapies that target immune dysregulation to restore the body’s natural biological balance.
Administered intravenously and built for real-world veterinary practice, these therapies are being developed to target the root causes of disease, helping expand the spectrum of care for challenging conditions.
These therapies are investigational and not available for general use, but may be accessible through participation in a clinical trial.
Refractory Feline Chronic Gingivostomatitis
Feline chronic gingivostomatitis (FCGS) is a painful oral disease that affects approximately 10% of cats and can be resistant to standard treatments. Gallant is evaluating a stem cell therapy designed to restore quality of life by addressing the underlying inflammation and promoting healing of oral lesions.
Feline Osteoarthritis
Osteoarthritis affects mobility, comfort, and daily activity, particularly in older cats, and is often underdiagnosed and undertreated. Gallant’s investigational therapy is designed to improve mobility and comfort by reducing inflammation and supporting joint repair.
Canine Osteoarthritis
Enrollment for this clinical trial is now complete.
Osteoarthritis affects mobility, comfort, and daily activity in both young and older dogs. Gallant’s investigational therapy is designed to reduce inflammation and support joint health.
Feline Chronic Kidney Disease
Enrollment for this clinical trial is now complete.
Chronic kidney disease (CKD) is one of the most common and progressive conditions affecting older cats. Gallant’s investigational therapy is designed to target inflammation and support kidney health.
Canine Atopic Dermatitis
Enrollment for this clinical trial is now complete.
Atopic dermatitis in dogs can cause chronic itching, skin damage, and discomfort. Gallant’s investigational therapy is designed to reduce inflammation and improve skin barrier function.
Interested in our clinical studies?
*All therapies are investigational and not yet FDA-approved
